Patents by Inventor Mark S Leung

Mark S Leung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12251150
    Abstract: Neuromodulation cryotherapeutic devices and associated systems and methods are disclosed herein. A cryotherapeutic device configured in accordance with a particular embodiment of the present technology can include an elongated shaft having distal portion and a supply lumen along at least a portion of the shaft. The shaft can be configured to locate the distal portion intravascularly at a treatment site proximate a renal artery or renal ostium. The supply lumen can be configured to receive a liquid refrigerant. The cryotherapeutic device can further include a cooling assembly at the distal portion of the shaft. The cooling assembly can include an applicator in fluid communication with the supply lumen and configured to deliver cryotherapeutic cooling to nerves proximate the target site when the cooling assembly is in a deployed state.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: March 18, 2025
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Naomi Buckley, Benjamin J Clark, Michael Cummins, Danny Donovan, Mark Gelfand, Luke Hughes, Brian Kelly, Gary Kelly, Grace Kelly, John Kelly, Mark S. Leung, Gwenda Francis, Barry Mullins, Karun D. Naga, Stephen Nash, Eric Ryba, Fiachra Sweeney, Vincenzo Tilotta, Roman Turovskiy, Lana Woolley, Denise Zarins, Michael Turovskiy
  • Publication number: 20240335226
    Abstract: The present disclosure relates to devices, systems and methods for evaluating the success of a treatment applied to tissue in a patient, such as a radio frequency ablative treatment used to neuromodulate nerves associated with the renal artery. A system monitors parameters or values generated during the course of a treatment. Feedback provided to an operator is based on the monitored values and relates to an assessment of the likelihood that a completed treatment was technically successful. In other embodiments, parameters or values generated during the course of an incomplete treatment (such as due to high temperature or high impedance conditions) may be evaluated to provide additional instructions or feedback to an operator.
    Type: Application
    Filed: June 20, 2024
    Publication date: October 10, 2024
    Inventors: Sowmya Ballakur, Robert J. Beetel, Paul Friedrichs, David Herzfeld, Andrew Wu, Denise Zarins, Mark S. Leung
  • Patent number: 12035959
    Abstract: The present disclosure relates to devices, systems and methods for evaluating the success of a treatment applied to tissue in a patient, such as a radio frequency ablative treatment used to neuromodulate nerves associated with the renal artery. A system monitors parameters or values generated during the course of a treatment. Feedback provided to an operator is based on the monitored values and relates to an assessment of the likelihood that a completed treatment was technically successful. In other embodiments, parameters or values generated during the course of an incomplete treatment (such as due to high temperature or high impedance conditions) may be evaluated to provide additional instructions or feedback to an operator.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: July 16, 2024
    Assignee: Medtronic Ireland Manufacturing Unlimited Company
    Inventors: Sowmya Ballakur, Robert J. Beetel, Paul Friedrichs, David Herzfeld, Andrew Wu, Denise Zarins, Mark S. Leung
  • Publication number: 20240156521
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Application
    Filed: June 9, 2023
    Publication date: May 16, 2024
    Inventors: Dorin PANESCU, Andrew WU, Zoar Jacob ENGELMAN, Mark GELFAND, Mark S. LEUNG, Howard LEVIN
  • Patent number: 11844569
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue are disclosed herein. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Grant
    Filed: August 15, 2023
    Date of Patent: December 19, 2023
    Assignee: Axon Therapies, Inc.
    Inventors: Dorin Panescu, Andrew Wu, Zoar Jacob Engelman, Mark Gelfand, Mark S. Leung
  • Publication number: 20230380901
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue are disclosed herein. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Application
    Filed: August 15, 2023
    Publication date: November 30, 2023
    Inventors: Dorin PANESCU, Andrew WU, Zoar Jacob ENGELMAN, Mark GELFAND, Mark S. LEUNG
  • Publication number: 20230380896
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue are disclosed herein. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Application
    Filed: August 7, 2023
    Publication date: November 30, 2023
    Inventors: Dorin PANESCU, Andrew WU, Zoar Jacob ENGELMAN, Mark GELFAND, Mark S. LEUNG
  • Publication number: 20230346380
    Abstract: A flow control device (300, 324, 330) for a bronchial passageway including: a flow control valve (307, 335); a braided wire structural frame (303) expandable from a collapsed configuration to an expanded configuration, in the collapsed configuration the frame is an extended tube and in the collapsed configuration the frame includes a wall contact section (310), a middle support section (312) within the wall contact section, and a fold (311) between and connecting the wall contact section and the middle support section; and a sealing membrane (305) mounted to at least a distal portion of the structural frame, wherein the sealing membrane forms an enclosed wall defining at least a portion of an airflow passage through the flow control device, and the flow control valve is included in the airflow passage and extending inward from the enclosed wall and at least partially within the wall contact section.
    Type: Application
    Filed: January 22, 2021
    Publication date: November 2, 2023
    Inventors: Sean TOTTEN, Residenc LEE, Joe M. GUERRICABEITIA, Don TANAKA, Abha Prashant CHINUBHA, Mark S. LEUNG, Lucas SANTANNA, Claudia PHAM, Abigail BRAZIL
  • Patent number: 11801092
    Abstract: Apparatuses and methods for treating a heart failure patient by ablating a nerve of the thoracic splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method comprising: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects and monitoring for presence of the lung in the ablation zone. An alternative method comprising: inserting a catheter into a vein adjacent the nerve, detecting that lung tissue is a safe distance from an ablation zone, and delivering ablation energy to the target nerve when lung tissue is a safe distance from the ablation zone.
    Type: Grant
    Filed: October 26, 2021
    Date of Patent: October 31, 2023
    Assignee: Axon Therapies, Inc.
    Inventors: Howard Levin, Mark Gelfand, Zoar Jacob Engelman, Dorin Panescu, Mark S. Leung
  • Patent number: 11751939
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue are disclosed herein. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: September 12, 2023
    Assignee: Axon Therapies, Inc.
    Inventors: Dorin Panescu, Andrew Wu, Zoar Jacob Engelman, Mark Gelfand, Mark S. Leung
  • Patent number: 11712296
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: August 1, 2023
    Assignee: Axon Therapies, Inc.
    Inventors: Dorin Panescu, Andrew Wu, Zoar Jacob Engelman, Mark Gelfand, Mark S. Leung, Howard Levin
  • Publication number: 20220257315
    Abstract: Apparatuses and methods for treating a heart failure patient by ablating a nerve of the thoracic splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method comprising: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects and monitoring for presence of the lung in the ablation zone. An alternative method comprising: inserting a catheter into a vein adjacent the nerve, detecting that lung tissue is a safe distance from an ablation zone, and delivering ablation energy to the target nerve when lung tissue is a safe distance from the ablation zone.
    Type: Application
    Filed: October 26, 2021
    Publication date: August 18, 2022
    Inventors: Howard LEVIN, Mark GELFAND, Zoar Jacob ENGELMAN, Dorin PANESCU, Mark S. LEUNG
  • Patent number: 11154354
    Abstract: Apparatuses and methods for treating a heart failure patient by ablating a nerve of the thoracic splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method comprising: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying stimulation energy after the ablation and observing hemodynamic effects and monitoring for presence of the lung in the ablation zone. An alternative method comprising: inserting a catheter into a vein adjacent the nerve, detecting that lung tissue is a safe distance from an ablation zone, and delivering ablation energy to the target nerve when lung tissue is a safe distance from the ablation zone.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: October 26, 2021
    Assignee: Axon Therapies, Inc.
    Inventors: Howard Levin, Mark Gelfand, Zoar Jacob Engelman, Dorin Panescu, Mark S. Leung
  • Publication number: 20210259760
    Abstract: The present disclosure relates to devices, systems and methods for evaluating the success of a treatment applied to tissue in a patient, such as a radio frequency ablative treatment used to neuromodulate nerves associated with the renal artery. A system monitors parameters or values generated during the course of a treatment. Feedback provided to an operator is based on the monitored values and relates to an assessment of the likelihood that a completed treatment was technically successful. In other embodiments, parameters or values generated during the course of an incomplete treatment (such as due to high temperature or high impedance conditions) may be evaluated to provide additional instructions or feedback to an operator.
    Type: Application
    Filed: May 7, 2021
    Publication date: August 26, 2021
    Inventors: Sowmya Ballakur, Robert J. Beetel, Paul Friedrichs, David Herzfeld, Andrew Wu, Denise Zarins, Mark S. Leung
  • Patent number: 11006999
    Abstract: The present disclosure relates to devices, systems and methods for evaluating the success of a treatment applied to tissue in a patient, such as a radio frequency ablative treatment used to neuromodulate nerves associated with the renal artery. A system monitors parameters or values generated during the course of a treatment. Feedback provided to an operator is based on the monitored values and relates to an assessment of the likelihood that a completed treatment was technically successful. In other embodiments, parameters or values generated during the course of an incomplete treatment (such as due to high temperature or high impedance conditions) may be evaluated to provide additional instructions or feedback to an operator.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: May 18, 2021
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Sowmya Ballakur, Robert J. Beetel, Paul Friedrichs, David Herzfeld, Andrew Wu, Denise Zarins, Mark S. Leung
  • Publication number: 20210128229
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue are disclosed herein. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Application
    Filed: January 28, 2019
    Publication date: May 6, 2021
    Applicant: AXON THERAPIES, INC.
    Inventors: Dorin PANESCU, Andrew WU, Zoar Jacob ENGELMAN, Mark GELFAND, Mark S. LEUNG
  • Publication number: 20210068886
    Abstract: Neuromodulation cryotherapeutic devices and associated systems and methods are disclosed herein. A cryotherapeutic device configured in accordance with a particular embodiment of the present technology can include an elongated shaft having distal portion and a supply lumen along at least a portion of the shaft. The shaft can be configured to locate the distal portion intravascularly at a treatment site proximate a renal artery or renal ostium. The supply lumen can be configured to receive a liquid refrigerant. The cryotherapeutic device can further include a cooling assembly at the distal portion of the shaft. The cooling assembly can include an applicator in fluid communication with the supply lumen and configured to deliver cryotherapeutic cooling to nerves proximate the target site when the cooling assembly is in a deployed state.
    Type: Application
    Filed: November 16, 2020
    Publication date: March 11, 2021
    Inventors: Naomi Buckley, Benjamin J. Clark, Michael Cummins, Danny Donovan, Mark Gelfand, Luke Hughes, Brian Kelly, Gary Kelly, Grace Kelly, John Kelly, Mark S. Leung, Gwenda Francis, Barry Mullins, Karun D. Naga, Stephen Nash, Eric Ryba, Fiachra Sweeney, Vincenzo Tilotta, Roman Turovskiy, Lana Woolley, Denise Zarins, Michael Turovskiy
  • Patent number: 10842547
    Abstract: Neuromodulation cryotherapeutic devices and associated systems and methods are disclosed herein. A cryotherapeutic device configured in accordance with a particular embodiment of the present technology can include an elongated shaft having distal portion and a supply lumen along at least a portion of the shaft. The shaft can be configured to locate the distal portion intravascularly at a treatment site proximate a renal artery or renal ostium. The supply lumen can be configured to receive a liquid refrigerant. The cryotherapeutic device can further include a cooling assembly at the distal portion of the shaft. The cooling assembly can include an applicator in fluid communication with the supply lumen and configured to deliver cryotherapeutic cooling to nerves proximate the target site when the cooling assembly is in a deployed state.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: November 24, 2020
    Assignee: MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L.
    Inventors: Naomi Buckley, Benjamin J. Clark, Michael Cummins, Danny Donovan, Mark Gelfand, Luke Hughes, Brian Kelly, Gary Kelly, Grace Kelly, John Kelly, Mark S. Leung, Gwenda Francis, Barry Mullins, Karun D. Naga, Stephen Nash, Eric Ryba, Fiachra Sweeney, Vincenzo Tilotta, Roman Turovskiy, Lana Woolley, Denise Zarins, Michael Turovskiy
  • Publication number: 20200179045
    Abstract: Apparatuses and methods for treating a heart failure patient by ablating a nerve of the thoracic splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method comprising: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying stimulation energy after the ablation and observing hemodynamic effects and monitoring for presence of the lung in the ablation zone. An alternative method comprising: inserting a catheter into a vein adjacent the nerve, detecting that lung tissue is a safe distance from an ablation zone, and delivering ablation energy to the target nerve when lung tissue is a safe distance from the ablation zone.
    Type: Application
    Filed: July 31, 2017
    Publication date: June 11, 2020
    Applicant: AXON THERAPIES, INC.
    Inventors: Howard LEVIN, Mark GELFAND, Zoar Jacob ENGELMAN, Dorin PANESCU, Mark S. LEUNG
  • Publication number: 20200179047
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Application
    Filed: February 18, 2020
    Publication date: June 11, 2020
    Inventors: Dorin PANESCU, Andrew WU, Zoar Jacob ENGELMAN, Mark GELFAND, Mark S. LEUNG, Howard LEVIN